I thought it was interesting. The first half of the discussion was indeed mostly about prostate cancer, but it's worth hanging in until the end. No new bombshells, of course - when the discussion shifted to CFS you can hear everyone getting VERY careful of how they choose their words.
I've only had a chance for one listen-through and haven't made any notes, but what struck me was how much research just this *one* researcher is involved with. I hear no indication that the XMRV/CFS connection is looking like a dead end or that anyone is taking the negative studies as closing the discussion. As Garcia mentioned, Dr. Singh placed a lot of emphasis on how difficult XMRV is to find. In her current study, she is using multiple assays (it sounded like a very thorough effort) to look for XMRV in CFS patients and healthy controls from the Salt Lake City area - 100 PWCs and 200 healthy controls, so a good-sized group. I didn't hear her say clearly what clinical definition they used in selecting the CFS patients, but they were referred from physicians.
The TWiV guys were all clamoring to know whether she was exchanging samples with the WPI's patient group. I sensed that they were all frustrated this hasn't happened with the other "negative" studies. She explained that she is getting samples from the WPI's patients, in such a way as to eliminate any possibility of contamination from the WPI lab - patients are identified, phlebotomists go to the patients (it sounded to me like they actually go to their houses!), draw fresh samples and then send the samples directly to Dr. Singh's laboratory in Utah. This is ongoing right now and they will get about 18 total samples in this manner.
There was also a description of a 1 1/2 year study of autopsies, both male and female, looking for XMRV and casting a very wide net about what medical conditions XMRV might be associated with. I'll have to listen again to understand that one better.
Dr. Singh also said they are looking at cervical fluid from women to see if XMRV is turning up there.